Evidence map›Paper›PMID 40940662›Full record

ArticleBMC public health2025

The global, regional, and National burden of parkinson's disease in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021.

Yaqiang Li, Zhi Lv, Yulong Dai, Liuzhenxiong Yu, Lin Zhang, Kai Wang, Panpan Hu

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Discovery of Sennoside A as a NaturalResearch (Washington, D.C.) · 2026
    Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yaqiang Li *Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhi Lv *Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Yulong DaiDepartment of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Liuzhenxiong YuDepartment of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Lin ZhangThe School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Lin.zhang2@monash.edu.
Kai WangDepartment of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China. Wangkai1964@126.com.
Panpan HuDepartment of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China. hupanpan@ahmu.edu.cn.

Funding

National Natural Science Foundation of China 81971689National Natural Science Foundation of China 82471271
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) represents a prevalent neurodegenerative condition that leads to significant disability and contributes to a growing public health challenge worldwide. However, a comprehensive report on progress from 1990 to 2021 is still lacking, especially regarding the risk factors associated with PD by gender and age. This study aims to examine the patterns of PD incidence, mortality rates, and disability-adjusted life years (DALYs) across all age groups, along with the risk factors linked to PD-related fatalities, spanning the years from 1990 to 2021.

methodsWe retrieved data on PD from the Global Burden of Disease Study 2021. The burden of PD was assessed using incidence, deaths, and DALYs, with corresponding 95% uncertainty interval (UI). Analyses were conducted globally, regionally, and nationally for the period between 1990 and 2021, stratified by age, sex, and the Socio-demographic Index (SDI). Estimated annual percentage changes (EAPCs) were calculated to assess temporal trends. Only cases directly attributable to PD were included, and a comorbidity correction was applied to ensure accurate estimation of the burden.

resultsIn 2021, there were 13.35 million (95% UI: 12.67-14.08) incident cases and 388,194 (95% UI: 347,250-417,388) deaths cases globally. The global DALYs attributed to PD climbed from 53.51 to 94.68 per 100,000 population (95% UI: 49.54-57.56 to 85.37-103.11) from 1990 to 2021. During the same period, age-standardized incidence rates rose from 7.82 to 16.92 per 100,000 population (95% UI: 6.95-8.75 to 15.16-18.82), while mortality rates increased from 2.78 to 4.91 per 100,000 population (95% UI: 2.55-2.97 to 4.40-5.29). Among the five SDI regions, the high SDI region reported the highest PD mortality rate in 2021. The burden of PD was most pronounced in the 85-89 age group. Smoking was identified as a key risk factor for PD-associated mortality in 2021, with the proportion of deaths attributable to smoking ranging from - 9.09% in individuals aged 50-54 years to -2.69% in those aged 95 years and older.

conclusionsPD represents a significant and escalating global health challenge, driven by increasing incidence rates and an aging population. This growing burden highlights the urgent need for effective strategies in prevention, early diagnosis, and tailored management, particularly for elderly males who are disproportionately affected. Addressing modifiable risk factors and advancing etiological research are crucial to mitigating the rising prevalence and optimizing resource allocation. Coordinated public health interventions and robust healthcare policies are essential to reduce the global impact of PD and improve outcomes for affected individuals.

Indexed as

Global Burden of DiseaseGlobal HealthParkinson DiseaseAdolescentAdultAgedAged, 80 and overDisability-Adjusted Life YearsFemaleHumansIncidenceMaleMiddle AgedQuality-Adjusted Life YearsRisk FactorsYoung AdultDisability-adjusted life yearsGlobal burden of diseaseIncidenceMortalityParkinson’s diseaseRisk

Identifiers

PMID40940662
PMCPMC12427116

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.